HUS offers antibody treatment for babies against RSV
The Hospital District of Helsinki and Uusimaa (HUS) has launched a new initiative aimed at protecting young children from the severe respiratory syncytial virus (RSV). The hospital is offering antibody treatment to children under 12 months of age who belong to a high-risk group.
RSV, or respiratory syncytial virus, is a common respiratory infection that can cause serious symptoms, such as breathing difficulties, especially in infants. The goal of the new treatment is to reduce the number of infections requiring hospitalization and to improve the health of children in the high-risk group.
Antibody treatment is a preventive measure that provides the child's body with protection against the virus. According to HUS, the treatment is aimed specifically at those infants who are at the highest risk of becoming severely ill. The treatment is part of a broader effort to improve the management and prevention of infections in children in Finland.
Parents whose children are in the high-risk group will receive more information about the treatment from their own healthcare providers. Experts remind that good hand hygiene and avoiding contact with sick individuals remain important ways to protect young children from viral infections.